262 related articles for article (PubMed ID: 8097280)
1. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Bravi D; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
[TBL] [Abstract][Full Text] [Related]
2. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN
Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
[TBL] [Abstract][Full Text] [Related]
3. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
4. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
[TBL] [Abstract][Full Text] [Related]
6. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
[No Abstract] [Full Text] [Related]
7. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
[TBL] [Abstract][Full Text] [Related]
8. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
Crossman AR
Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of dyskinesias in Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
[TBL] [Abstract][Full Text] [Related]
10. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease. The L-dopa era.
Yahr MD
Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
[No Abstract] [Full Text] [Related]
12. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
[TBL] [Abstract][Full Text] [Related]
13. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
[TBL] [Abstract][Full Text] [Related]
14. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Varanese S; Howard J; Di Rocco A
Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
[No Abstract] [Full Text] [Related]
15. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
16. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
17. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
18. Clinical physiology of dopa dyskinesia.
Hallett M
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
[TBL] [Abstract][Full Text] [Related]
19. Milacemide therapy for Parkinson's disease.
Giuffra ME; Sethy VH; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
[TBL] [Abstract][Full Text] [Related]
20. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]